Fig. 3

Flowchart of patient selection in the Dokkyo study (Validation cohort). Out of 230 patients who underwent curative surgery for pancreatic cancer, 119 were excluded due to non-S-1 treatment or early recurrence. Ultimately, 111 patients were included in the validation cohort.